In a document dated 2022 September 20th, European countries are recommended to use organized PCa screening programs for men aged ≤70 years on the basis of their PSA concentrations, in combination with follow-up magnetic resonance imaging [33, 34]. The gene discussed is KLK3; the disease is posterior cortical atrophy.